0001209191-13-007128.txt : 20130207 0001209191-13-007128.hdr.sgml : 20130207 20130207173234 ACCESSION NUMBER: 0001209191-13-007128 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130205 FILED AS OF DATE: 20130207 DATE AS OF CHANGE: 20130207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MUELLER PETER CENTRAL INDEX KEY: 0001256126 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 13583548 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6173416100 MAIL ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2013-02-05 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001256126 MUELLER PETER C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE MA 02139 0 1 0 0 EVP, Global R&D, CSO Common Stock 2013-02-05 4 A 0 12084 0.01 A 144400 D Common Stock 4664 I 401(k) Employee Stock Option (right to buy) 45.11 2013-02-05 4 A 0 54375 0.00 A 2023-02-04 Common Stock 54375 54375 D Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Omar White, Attorney-In-Fact 2013-02-07